A phase 3, randomized, active-controlled trial will evaluate the efficacy and safety of a HIF-2α inhibitor for the second-line treatment of clear cell RCC. MK-6482, a HIF-2α inhibitor, has moved into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results